October 09, 2019
1 min read
Save

Dermira begins phase 3 study of lebrikizumab in atopic dermatitis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Dermira announced treatment commencement in the first patient for a phase 3 study evaluating lebrikizumab in adult and adolescents with moderate to severe atopic dermatitis.

Lebrikizumab is an investigational, monoclonal antibody designed to bind to interleukin-13 (IL-13) to prevent the formation of the IL-13 receptor alpha/IL-4 receptor alpha heterodimer complex and signaling, according to the company press release.

The phase 3 study encompasses two identical, randomized, double-blind, placebo-controlled studies across 200 sites in the U.S., Europe and Asia.

Eight hundred adolescents and adults aged at least 12 years presenting with chronic atopic dermatitis for at least 1 year are expected to enroll.

After a loading dose of lebrikizumab 500 mg at baseline and week 2, the studies will evaluate lebrikizumab 250 mg injection every 2 weeks vs. placebo for 16 weeks.

After week 16, those who respond via a reduction of at least 2 points in the Investigator’s Global Assessment score from baseline to final score (the primary endpoint of the study) or with an Eczema Area Severity Index (EASI)-75 response, will be re-randomized into one of three treatment groups for an additional 36 weeks:

  • lebrikizumab 250 mg every 2 weeks;
  • lebrikizumab 250 mg every 4 weeks; or
  • placebo given every 2 weeks.

Those who do not achieve the week-16 benchmarks and patients who do not maintain an EASI-50 during the maintenance period will be assigned an open-label treatment of lebrikizumab 250 mg, every 2 weeks through week 52.

The company expects to announce the 16-week induction period data in the first half of 2021. Additionally, plans are underway to include a study in this program to evaluate lebrikizumab when used in combination with topical corticosteroids, according to the release.